Pfizer Ltd.

PFIZER

Market Cap
₹18,847 Cr.
P/E
37.53

Pfizer Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Unable to calculate due to limited data
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years but more due to rerating
ROE
Financial Leverage has increased ROE over 10 years
Working Capital
Working Capital of the company seems to be under control
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a premium to 3 year historic valuations
ROE
Latest
19.45%
3yr Average
20.54%
5yr Average
18.17%
Net Profit Margin
Latest
25.73%
3yr Average
23.81%
5yr Average
23.14%
ROCE
Latest
24.79%
3yr Average
26.17%
5yr Average
23.74%
Debt to Equity
Latest
0.0
3yr Average
0.0
5yr Average
0.0
Market Share
17% (as of Mar 23)
Antacid (Gelucil) - Market Share
locked Source
0% (as of Jul 22)
Anti - Diabetes - Market Share
2.98% (as of Jul 22)
Anti-Infectives - Market Share
0.14% (as of May 19)
Anti-Malarial - Market Share
67% (as of Mar 23)
Anticholinergics ( Pacitane) - Market Share
locked Source
2.34% (as of Nov 21)
Antineo Plastic - Market Share
75.10% (as of Mar 21)
Becosules - Market Share
locked Source
6.08% (as of Nov 21)
Blood Related - Market Share
1.88% (as of Jul 22)
Cardiovascular - Market Share
39% (as of Mar 19)
Cefoperazone Sulbactam - Market Share
locked Source
15.30% (as of Mar 23)
Corex Dx - Market Share
locked Source
0.05% (as of Nov 21)
Dermatology - Market Share
29.70% (as of Mar 22)
Eliquis - Market Share
locked Source
30% (as of Mar 19)
Enbrel - Market Share
locked Source
11.34% (as of Nov 21)
Endocrinology - Market Share
7.50% (as of Mar 19)
Folvite - Market Share
locked Source
1.82% (as of Jul 22)
Gastro-Intestinal - Market Share
4.45% (as of Nov 21)
Gynecology - Market Share
45% (as of Mar 23)
Hypertension (Minipress) - Market Share
locked Source
1% (as of Mar 19)
Lyrica - Market Share
locked Source
6.70% (as of Mar 23)
Magnex - Market Share
locked Source
5.50% (as of Mar 23)
Meronem - Market Share
locked Source
2.72% (as of Nov 21)
Neurological - Market Share
1.15% (as of Nov 21)
Ophthalmology - Market Share
1.78% (as of Nov 21)
Pain - Market Share
1.70% (as of Dec 22)
Pharmaceutical Sector - Market Share
1.87% (as of Nov 21)
Respiratory - Market Share
1.96% (as of Jul 22)
Sex Stimulants - Market Share
0.01% (as of Nov 21)
Stomatological - Market Share
2.40% (as of Nov 21)
Urology - Market Share
3.58% (as of Jul 22)
Vaccines - Market Share
2.66% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • Domestic Sales Growth - YoY (%)
      Source
    Peer Comparison
    Brands
    Autrin
    Becosules
    Corex Dx
    Gelusil
    Ovral L
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline